Drugs / Homologous mRNA booster vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05142319 Comparator | Oct 2021 → Jun 2023 | COVID-19 | Tan Tock Seng Hospital | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Homologous mRNA booster vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142319 ↗ |
| Modality | Messenger RNA (mRNA) | “two mRNA vaccines (BNT162b2 and mRNA-1273)” PMID 35710572 ↗ Jun 2022 |
| Route | Other | “Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.” NCT05142319 ↗ |